PuSH - Publication Server of Helmholtz Zentrum München: An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia.

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

EVA: Electronic Publishing

New EVA Application

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Metzeler, K.H.* ; Hummel, M.* ; Bloomfield, C.D.* ; Spiekermann, K. ; Braess, J.* ; Sauerland, M.C.* ; Heinecke, A.* ; Radmacher, M.* ; Marcucci, G.* ; Whitman, SP.* ; Maharry, K.* ; Paschka, P.* ; Larson, R.A.* ; Berdel, W.E.* ; Büchner, T.* ; Wörmann, B.* ; Mansmann, U.* ; Hiddemann, W. ; Bohlander, S.K. ; Buske, C. ; Cancer and Leukemia Group B (*) ; German AML Cooperative Group (*)

An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia.

Blood 112, 4193-4201 (2008)

DOI

Open Access Green as soon as Postprint is submitted to ZB.

Abstract
Metrics
Extra information

Patients with cytogenetically normal acute myeloid leukemia (CN-AML) show heterogeneous treatment outcomes. We used gene-expression profiling to develop a gene signature that predicts overall survival (OS) in CN-AML. Based on data from 163 patients treated in the German AMLCG 1999 trial and analyzed on oligonucleotide microarrays, we used supervised principal component analysis to identify 86 probe sets (representing 66 different genes), which correlated with OS, and defined a prognostic score based on this signature. When applied to an independent cohort of 79 CN-AML patients, this continuous score remained a significant predictor for OS (hazard ratio [HR], 1.85; P = .002), event-free survival (HR = 1.73; P = .001), and relapse-free survival (HR = 1.76; P = .025). It kept its prognostic value in multivariate analyses adjusting for age, FLT3 ITD, and NPM1 status. In a validation cohort of 64 CN-AML patients treated on CALGB study 9621, the score also predicted OS (HR = 4.11; P < .001), event-free survival (HR = 2.90; P < .001), and relapse-free survival (HR = 3.14, P < .001) and retained its significance in a multivariate model for OS. In summary, we present a novel gene-expression signature that offers additional prognostic information for patients with CN-AML.

Impact Factor

Scopus SNIP

Web of Science
Times Cited

Scopus
Cited By

Altmetric

10.896

3.020

161

234